The DOI matches its Crossref record; 774 of the 774 references it cites were found in a registry or an index.
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Abstract
A number of therapeutic drugs with different structures and mechanisms of action have been reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes. The bioactivation gives rise to reactive metabolites/intermediates, which readily confer covalent binding to various target proteins by nucleophilic substitution and/or Schiff's base mechanism. These drugs include analgesics (e.g., acetaminophen), antibacterial agents (e.g., sulfonamides and macrolide antibiotics), anticancer drugs (e.g., irinotecan), antiepileptic drugs (e.g., carbamazepine), anti-HIV agents (e.g., ritonavir), antipsychotics (e.g., clozapine), cardiovascular drugs (e.g., procainamide and hydralazine), immunosupressants (e.g., cyclosporine A), inhalational anesthetics (e.g., halothane), nonsteroidal anti-inflammatory drugs (NSAIDSs) (e.g., diclofenac), and steroids and their receptor modulators (e.g., estrogens and tamoxifen). Some herbal and dietary constituents are also bioactivated to reactive metabolites capable of binding covalently and inactivating cytochrome P450s (CYPs). A number of important target proteins of drugs have been identified by mass spectrometric techniques and proteomic approaches. The covalent binding and formation of drug-protein adducts are generally considered to be related to drug toxicity, and selective protein covalent binding by drug metabolites may lead to selective organ toxicity. However, the mechanisms involved in the protein adduct-induced toxicity are largely undefined, although it has been suggested that drug-protein adducts may cause toxicity either through impairing physiological functions of the modified proteins or through immune-mediated mechanisms. In addition, mechanism-based inhibition of CYPs may result in toxic drug-drug interactions. The clinical consequences of drug bioactivation and covalent binding to proteins are unpredictable, depending on many factors that are associated with the administered drugs and patients. Further studies using proteomic and genomic approaches with high throughput capacity are needed to identify the protein targets of reactive drug metabolites, and to elucidate the structure-activity relationships of drug's covalent binding to proteins and their clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 774
Lahiri-Chatterjee, M., Katiyar, S. K., Mohan, R. R., & Agarwal, R. (1999) · PubMed · Cited by 208
Bourdi, M., Larrey, D., Nataf, J., Bernuau, J., Pessayre, D., Iwasaki, M., Guengerich, F. P., & Beaune, P. H. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114660 · Cited by 207
Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents
Luduena, R. F., & Roach, M. C. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90027-j · Cited by 207
Coles, B., Wilson, I., Wardman, P., Hinson, J. A., Nelson, S. D., & Ketterer, B. (1988) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(88)90592-9 · Cited by 205
Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
Veronese, M. E., Mackenzie, P. I., Doecke, C. J., McManus, M. E., Miners, J. O., & Birkett, D. J. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91680-b · Cited by 204
Effect of grapefruit juice on blood cyclosporin concentration
Yee, G. C., Stanley, D. L., Pessa, L. J., Costa, T. D., Beltz, S. E., Ruiz, J., & Lowenthal, D. T. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90700-9 · Cited by 203
Bioactivation of mutagens via sulfation
Glatt, H. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.5.9141497 · Cited by 200
Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson???s Disease
Kaakkola, S. (2000) · Drugs · doi:10.2165/00003495-200059060-00004 · Cited by 200
Bajpai, M., Roskos, L. K., Shen, D. D., & Levy, R. H. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08481-8 · Cited by 199
Acute Hepatitis Associated with the Chinese Herbal Product Jin Bu Huan
Woolf, G. M., Petrovic, L. M., Rojter, S. E., Wainwright, S., Villamil, F. G., Katkov, W. N., Michieletti, P., Wanless, I. R., Stermitz, F. R., Beck, J. J., et al. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-10-199411150-00001 · Cited by 196
Girard, P.-M., Landman, R., Gaudebout, C., Olivares, R., Saimot, A. G., Jelazko, P., Gaudebout, C., Certain, A., Boue, F., Bouvet, E., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305273282102 · Cited by 192
Ohyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, H., & Yokoi, T. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00134.x · Cited by 190
An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic.
Foster, B. C., Foster, M. S., Vandenhoek, S., Krantis, A., Budzinski, J. W., Arnason, J. T., Gallicano, K., & Choudri, S. (2001) · PubMed · Cited by 189
Human Cytochrome P450 2E1 Is a Major Autoantigen Associated with Halothane Hepatitis
Bourdi, M., Chen, W., Peter, R. M., Martin, J. L., Buters, J. T. M., Nelson, S. D., & Pohl, L. R. (1996) · Chemical Research in Toxicology · doi:10.1021/tx960083q · Cited by 189
The lupus syndrome induced by hydralazine: a common complication with low dose treatment.
Cameron, H. A., & Ramsay, L. E. (1984) · BMJ · doi:10.1136/bmj.289.6442.410 · Cited by 188
Stedman, C. (2002) · Seminars in Liver Disease · doi:10.1055/s-2002-30104 · Cited by 188
Saltiel, E., & Ward, A. (1987) · Drugs · doi:10.2165/00003495-198734020-00003 · Cited by 186
Zimmerman, H. J. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70097-0 · Cited by 186
Lertratanangkoon, K., & Horning, M. G. (1982) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07827-4 · Cited by 186
Dorner, A. J., Wasley, L. C., Raney, P., Haugejorden, S., Green, M., & Kaufman, R. J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45843-7 · Cited by 185
Expression of cytochromes P450 in human breast tissue and tumors.
Huang, Z., Fasco, M. J., Figge, H. L., Keyomarsi, K., & Kaminsky, L. S. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07451-3 · Cited by 184
Kuhn, D. M., Arthur, R. E., Thomas, D. M., & Elferink, L. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731309.x · Cited by 183
Metabolic Activation of Diclofenac by Human Cytochrome P450 3A4: Role of 5-Hydroxydiclofenac
Shen, S., Marchick, M. R., Davis, M. R., Doss, G. A., & Pohl, L. R. (1999) · Chemical Research in Toxicology · doi:10.1021/tx9802365 · Cited by 183
Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., & Ratain, M. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1502 · Cited by 182
Li, A. P. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00051-0 · Cited by 181
Boelsterli, U. A., Zimmerman, H. J., & Kretz-Rommel, A. (1995) · Critical Reviews in Toxicology · doi:10.3109/10408449509089888 · Cited by 180
Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., & Berthou, F. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90131-n · Cited by 179
Acetaminophen-induced hepatotoxicity
Hinson, J. A., Pohl, L. R., Monks, T. J., & Gillette, J. R. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90278-2 · Cited by 179
Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates.
Ortiz de Montellano, P. R., & Kunze, K. L. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70669-3 · Cited by 178
Protein Glycation: Creation of Catalytic Sites for Free Radical Generation
Yim, M. B., Yim, H., Lee, C., Kang, S., & Chock, P. B. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05634.x · Cited by 177
Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer
Watanabe, J., Shimada, T., Gillam, E. M. J., Ikuta, T., Suemasu, K., Higashi, Y., Gotoh, O., & Kawajiri, K. (2000) · Pharmacogenetics · doi:10.1097/00008571-200002000-00004 · Cited by 176
Ma, B., Prueksaritanont, T., & Lin, J. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15118-5 · Cited by 176
Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase
Xu, Y., Stokes, A. H., Roskoski, R., & Vrana, K. E. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19981201)54:5<691::aid-jnr14>3.0.co;2-f · Cited by 175
Tolcapone and Hepatotoxic Effects
Olanow, C. W. (2000) · Archives of Neurology · doi:10.1001/archneur.57.2.263 · Cited by 173
Piver, B., Berthou, F., Dreano, Y., & Lucas, D. (2001) · Toxicology Letters · doi:10.1016/s0378-4274(01)00418-0 · Cited by 172
Selective Protein Arylation and Acetaminophen-Induced Hepatotoxicity
Cohen, S. D., & Khairallah, E. A. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037573 · Cited by 172
Haaz, M., Rivory, L. P., Riché, C., Vernillet, L., & Robert, J. (1998) · PubMed · Cited by 172
Lopez-Garcia, M. P., Dansette, P. M., & Mansuy, D. (1994) · Biochemistry · doi:10.1021/bi00167a022 · Cited by 171
Thalidomide metabolism by the CYP2C subfamily.
Ando, Y., Fuse, E., & Figg, W. D. (2002) · PubMed · Cited by 171
Cribb, A. E., Spielberg, S. P., & Griffin, G. P. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06552-3 · Cited by 169
Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinoshita, A., Ariyoshi, Y., Furuse, K., & Fukuoka, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1068 · Cited by 169
Fichtenbaum, C. J., & Gerber, J. G. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241140-00004 · Cited by 168
Sex-specific cytochrome P450 as a cause of sex-and species-related differences in drug toxicity
Kato, R., & Yamazoe, Y. (1992) · Toxicology Letters · doi:10.1016/0378-4274(92)90245-f · Cited by 168
Polymorphisms of CYP2A6 and its practical consequences
Raunio, H., Rautio, A., Gullstén, H., & Pelkonen, O. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01500.x · Cited by 167
Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis.
Eliasson, E., & Kenna, J. G. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09316-2 · Cited by 167
Herbals, Cancer Prevention and Health
Wargovich, M. J., Woods, C., Hollis, D. M., & Zander, M. E. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.11.3034s · Cited by 167
Ohyama, K., Nakajima, M., Nakamura, S., Shimada, N., Yamazaki, H., & Yokoi, T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15077-5 · Cited by 166
Ju, C., & Uetrecht, J. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337333 · Cited by 166
A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis.
Homberg, J., Andre, C., & Abuaf, N. (1984) · PubMed · Cited by 165
Acute hepatitis associated with the use of a Chinese herbal product, ma-huang.
Nadir, A., Agrawal, S., King, P. D., & Marshall, J. B. (1996) · PubMed · Cited by 164
The danger hypothesis—potential role in idiosyncratic drug reactions
Pirmohamed, M., Naisbitt, D. J., Gordon, F., & Park, B. K. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00255-x · Cited by 164
Shan, B., Medina, J. C., Santha, E., Frankmoelle, W. P., Chou, T.-C., Learned, R. M., Narbut, M. R., Stott, D., Wu, P., Jaen, J. C., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5686 · Cited by 164
Kroemer, H. K., & Klotz, U. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00005 · Cited by 163
Fatal Liver Failure in 16 Children with Valproate Therapy
Scheffner, D., Konig, S., Rauterberg‐Ruland, I., Kochen, W., Hofmann, W. J., & Unkelbach, S. (1988) · Epilepsia · doi:10.1111/j.1528-1157.1988.tb03757.x · Cited by 163
Acute Hepatic Failure Associated with the Use of Sodium Valproate: Report of Two Fatal Cases
Suchy, F. J., Balistreri, W. F., Buchino, J. J., Sondheimer, J. M., Bates, S. R., Kearns, G. L., Stull, J. D., & Bove, K. E. (1979) · New England Journal of Medicine · doi:10.1056/nejm197904263001706 · Cited by 163
Chu, X.-Y., Kato, Y., Niinuma, K., Sudo, K.-I., Hakusui, H., & Sugiyama, Y. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36601-7 · Cited by 161
Structural insights into CPT-11 activation by mammalian carboxylesterases
Bencharit, S., Morton, C. L., Howard-Williams, E. L., Danks, M. K., Potter, P. M., & Redinbo, M. R. (2002) · Nature Structural Biology · doi:10.1038/nsb790 · Cited by 161
Raloxifene: A Review of its Use in Postmenopausal Osteoporosis
Clemett, D., & Spencer, C. M. (2000) · Drugs · doi:10.2165/00003495-200060020-00013 · Cited by 161
THE METABOLISM OF THALIDOMIDE: THE SPONTANEOUS HYDROLYSIS OF THALIDOMIDE IN SOLUTION
SCHUMACHER, H., SMITH, R. L., & WILLIAMS, R. T. (1965) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1965.tb02053.x · Cited by 161
The Second Generation of COX-2 Inhibitors: What Advantages Do the Newest Offer?
Stichtenoth, D. O., & lich, J. R. C. F. (2003) · Drugs · doi:10.2165/00003495-200363010-00003 · Cited by 161
Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. P., & Yokoi, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14927-6 · Cited by 161
Mechanisms of NSAID-Induced Hepatotoxicity: Focus on Nimesulide
Boelsterli, U. A. (2002) · Drug Safety · doi:10.2165/00002018-200225090-00003 · Cited by 159
Fatal hepatitis after herbal tea
Mostefa-Kara, N., Pauwels, A., Pines, E., Biour, M., & Levy, V. (1992) · The Lancet · doi:10.1016/0140-6736(92)92209-x · Cited by 159
Irreversible binding of zomepirac to plasma protein in vitro and in vivo.
Smith, P. C., McDonagh, A. F., & Benet, L. Z. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112392 · Cited by 159
Wen, X., Wang, J., Kivistö, K. T., Neuvonen, P. J., & Backman, J. T. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01474.x · Cited by 158
Boelsterli, U. A. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337315 · Cited by 158
Ticlopidine as a Selective Mechanism-Based Inhibitor of Human Cytochrome P450 2C19
Ha-Duong, N.-T., Dijols, S., Macherey, A.-C., Goldstein, J. A., Dansette, P. M., & Mansuy, D. (2001) · Biochemistry · doi:10.1021/bi010254c · Cited by 158
Mechanisms of Idiosyncratic Hypersensitivity Reactions to Antiepileptic Drugs
Leeder, J. S. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01679.x · Cited by 158
Hanioka, N., Ozawa, S., Jinno, H., Ando, M., Saito, Y., & Sawada, J. (2001) · Xenobiotica · doi:10.1080/00498250110057341 · Cited by 158
The mechanism of the interaction between amiodarone and warfarin in humans
Heimark, L. D., Wienkers, L. C., Kunze, K. L., Gibaldi, M., Eddy, A. C., Trager, W. F., O’Reilly, R. A., & Goulart, D. A. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.39 · Cited by 158
Landi, M. T., Sinha, R., Lang, N. P., & Kadlubar, F. F. (1999) · PubMed · Cited by 157
Wen, X., Wang, J., Neuvonen, P. J., & Backman, J. T. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0396-3 · Cited by 157
Jones, D. C., Gunasekar, P. G., Borowitz, J. L., & Isom, G. E. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742296.x · Cited by 157
Gill, J., Heel, R. C., & Fitton, A. (1992) · Drugs · doi:10.2165/00003495-199243010-00007 · Cited by 156
Human CYP2C9 and CYP2A6 Mediate Formation of the Hepatotoxin 4-Ene-Valproic Acid
Sadeque, A. J. M., Fisher, M. B., Korzekwa, K. R., Gonzalez, F. J., & Rettie, A. E. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37076-4 · Cited by 155
Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., et al. (2002) · Chemical Research in Toxicology · doi:10.1021/tx0200109 · Cited by 154
Roles of Human Hepatic Cytochrome P450s 2C9 and 3A4 in the Metabolic Activation of Diclofenac
Tang, W., Stearns, R. A., Wang, R. W., Chiu, S.-H. L., & Baillie, T. A. (1999) · Chemical Research in Toxicology · doi:10.1021/tx9802217 · Cited by 153
Haque, M. E., Asanuma, M., Higashi, Y., Miyazaki, I., Tanaka, K.-I., & Ogawa, N. (2002) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00440-3 · Cited by 153
Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite.
Gordon, G., Spielberg, S. P., Blake, D. A., & Balasubramanian, V. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2545 · Cited by 153
Jones, D. R., Gorski, J. C., Hamman, M. A., Mayhew, B. S., Rider, S., & Hall, S. D. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35013-x · Cited by 152
Kent, U. M., Aviram, M., Rosenblat, M., & Hollenberg, P. F. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.6.709 · Cited by 152
Li, D. N., Seidel, A., Pritchard, M. P., Wolf, C. R., & Friedberg, T. (2000) · Pharmacogenetics · doi:10.1097/00008571-200006000-00008 · Cited by 152
Obermayer–Straub, P., Strassburg, C. P., & Manns, M. P. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80425-0 · Cited by 152
Henry, R. R. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70267-x · Cited by 152
Targeting HIV: antiretroviral therapy and development of drug resistance
Menéndez‐Arias, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02054-0 · Cited by 151
Holm, K. J., & Markham, A. (1999) · Drugs · doi:10.2165/00003495-199957040-00010 · Cited by 151
PROTEIN TARGETS OF XENOBIOTIC REACTIVE INTERMEDIATES
Pumford, N. R., & Halmes, N. C. (1997) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.91 · Cited by 151
Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4
Chan, W. K., & Delucchi, A. B. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00888-2 · Cited by 150
Reilly, T. P., Lash, L. H., Doll, M. A., Hein, D. W., Woster, P. M., & Svensson, C. K. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00985.x · Cited by 150
Dybing, E., Nelson, S. D., Mitchell, J. R., Sasame, H. A., & Gillette, J. R. (1976) · PubMed · Cited by 149
Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides.
Rieder, M. J., Uetrecht, J., Shear, N. H., & Spielberg, S. P. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24502-5 · Cited by 148
In Vitro Metabolism of Tolcapone to Reactive Intermediates: Relevance to Tolcapone Liver Toxicity
Smith, K. S., Smith, P. L., Heady, T. N., Trugman, J. M., Harman, W. D., & Macdonald, T. L. (2003) · Chemical Research in Toxicology · doi:10.1021/tx025569n · Cited by 147
Chiba, M., Hensleigh, M., Nishime, J. A., Balani, S. K., & Lin, J. H. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07348-9 · Cited by 146
Chen, Y., & Ung, C. Y. (2001) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(01)00109-7 · Cited by 146
Self-citationStickel, F., Egerer, G., & Seitz, H. K. (2000) · Public Health Nutrition · doi:10.1017/s1368980000000161 · Cited by 146
Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7
Gall, W. E., Zawada, G., Mojarrabi, B., Tephly, T. R., Green, M. D., Coffman, B. L., Mackenzie, P. I., & Radominska-p, A. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00088-6 · Cited by 145
Reist, M., Carrupt, P., Francotte, E. R., & Testa, B. (1998) · Chemical Research in Toxicology · doi:10.1021/tx9801817 · Cited by 145
Herbal hepatotoxicity: An expanding but poorly defined problem
Chitturi, S., & Farrell, G. C. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02349.x · Cited by 145
Spectrum of Efficacy of Valproate in 78 Rapid-Cycling Bipolar Patients
Calabrese, J. R., Markovitz, P. J., Kimmel, S. E., & Wagner, S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199202001-00008 · Cited by 144
Dwivedy, I., Devanesan, P. D., Cremonesi, P., Rogan, E. G., & Cavalieri, E. L. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00030a016 · Cited by 143
Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang, L., Wring, S. A., Woolley, J. L., Brouwer, K. R., Serabjit‐Singh, C. J., & Polli, J. W. (2001) · PubMed · Cited by 142
O'Regan, R. M., & Jordan, V. C. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00711-8 · Cited by 142
Roche, H. M., Zampelas, A., Knapper, J. M. E., WEBB, D. H., Brooks, C., Jackson, K. G., Wright, J. W., GOULD, B. J., Kafatos, A., Gibney, M. J., et al. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.3.552 · Cited by 142
Imaoka, S., Enomoto, K., Oda, Y., Asada, A., Fujimori, M., Shimada, T., Fujita, S., Guengerich, F. P., & Funae, Y. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23210-4 · Cited by 141
Naisbitt, D. J., Farrell, J., Gordon, S. F., Maggs, J. L., Burkhart, C., Pichler, W. J., Pirmohamed, M., & Park, B. K. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.628 · Cited by 141
Thalidomide: Emerging Role in Cancer Medicine
Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104043 · Cited by 141
Pharmacokinetic Interactions of the Macrolide Antibiotics
Ludden, T. M. (1985) · Clinical Pharmacokinetics · doi:10.2165/00003088-198510010-00003 · Cited by 140
Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs, L. L., Peter, R. M., Thompson, S. J., Rettie, A. E., & Trager, W. F. (1997) · PubMed · Cited by 140
Reactive Intermediates and The Dynamics of Glutathione Transferases
Rinaldi, R., Eliasson, E., Swedmark, S., & Morgenstern, R. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1053 · Cited by 140
DeGowin, R. L., Eppes, R. B., Powell, R. D., & Carson, P. E. (1966) · Europe PMC (PubMed Central) · Cited by 139
Metabolism of 17 α-ethynylestradiol in humans
Guengerich, F. P. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90431-p · Cited by 139
Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse
Gordon, W. P., Forte, A. J., McMurtry, R. J., Gal, J., & Nelson, S. D. (1982) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(82)90387-8 · Cited by 139
Anticonvulsant toxicity in vitro: possible role of arene oxides.
Spielberg, S. P., Gordon, G., Blake, D. A., Mellits, E. D., & Bross, D. (1981) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32544-9 · Cited by 139
Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases
Bock, K. W., Forster, A., Gschaidmeier, H., et al. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90437-2 · Cited by 138
Induction of Metabolism-Dependent and -Independent Neutrophil Apoptosis by Clozapine
Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Uetrecht, J., & Park, B. K. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12157-8 · Cited by 138
Satoh, H., Fukuda, Y., Anderson, D. K., Ferrans, V. J., Gillette, J. R., & Pohl, L. R. (1985) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22885-3 · Cited by 136
In Vivo 11β-HSD-2 Activity: Variability, Salt-Sensitivity, and Effect of Licorice
Ferrari, P., Sansonnens, A., Dick, B., & Frey, F. J. (2001) · Hypertension · doi:10.1161/hy1101.096112 · Cited by 136
Rivory, L. P., Haaz, M., Canal, P., Lokiec, F. M., Armand, J., & Robert, J. (1997) · PubMed · Cited by 136
Adessi, C., Miège, C., Albrieux, C., & Rabilloud, T. (1997) · Electrophoresis · doi:10.1002/elps.1150180124 · Cited by 135
Sulfotransferases: genetics and role in toxicology
Glatt, H. R., Engelke, C. E. H., Pabel, U., Teubner, W., Jones, A. L., Coughtrie, M. W. H., Andrae, U., Falany, C. N., & Meinl, W. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00214-3 · Cited by 134
Influence of Environmental Temperature on the Blood Pressure of Hypertensive Patients in Montreal
Kuneš, J., Tremblay, J., Bellavance, F., & Hamet, P. (1991) · American Journal of Hypertension · doi:10.1093/ajh/4.5.422 · Cited by 134
Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity
Naisbitt, D. J., Hough, S. J., Gill, H., Pirmohamed, M., Kitteringham, N. R., & Park, B. K. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702453 · Cited by 134
Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Berg, W. J., Ginsberg, M. S., Russo, P., Vuky, J., Yu, R., Bacik, J., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.302 · Cited by 133
The abacavir hypersensitivity reaction: A review
Clay, P. G. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80057-1 · Cited by 133
Cancer chemopreventive and therapeutic activities of red ginseng
Xiaoguang, C., Hongyan, L., Xiaohong, L., Zhaodi, F., Li, Y., Lihua, T., & Han, R. (1998) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(97)00133-5 · Cited by 132
Suhy, D. A., Simon, K. D., Linzer, D. I. H., & O’Halloran, T. V. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.14.9183 · Cited by 132
Spina, E., Avenoso, A., Facciolà, G., Salemi, M., Scordo, M. G., Giacobello, T., Madia, A. G., & Perucca, E. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200008000-00019 · Cited by 132
Pearce, R. E., Vakkalagadda, G. R., & Leeder, J. S. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1170 · Cited by 132
Lin, H.-L., Kent, U. M., & Hollenberg, P. F. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.160 · Cited by 132
Xia, Z., Lundgren, B., Bergstrand, A., DePierre, J. W., & Nässberger, L. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00009-x · Cited by 131
Miyamoto, G., ZAHID, N. D., & Uetrecht, J. (1997) · Chemical Research in Toxicology · doi:10.1021/tx960190k · Cited by 130
Acute hepatitis induced by Shou‐Wu‐Pian, a herbal product derived from Polygonum multiflorum
Park, G. J., Mann, S. P., & Ngu, M. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02309.x · Cited by 130
Winn, L. M., & Wells, P. G. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00340-1 · Cited by 129
Cytochrome P450 Enzyme System: Genetic Polymorphisms and Impact on Clinical Pharmacology
van der Weide, J., & Steijns, L. S. W. (1999) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329903600604 · Cited by 129
Anticancer therapy with novel tubulin-interacting drugs
Kavallaris, M., Verrills, N. M., & Hill, B. T. (2001) · Drug Resistance Updates · doi:10.1054/drup.2002.0230 · Cited by 129
Nortier, J., & Vanherweghem, J. L. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00486-9 · Cited by 129
Pisciotta, V. (1978) · Drugs · doi:10.2165/00003495-197815020-00003 · Cited by 129
Lekéhal, M., Pessayre, D., Lereau, J. M., Moulis, C., Fourasté, I., & Fau, D. (1996) · Hepatology · doi:10.1002/hep.510240134 · Cited by 128
Maggs, J. L., Williams, D. P., Pirmohamed, M., & Park, B. K. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12206-4 · Cited by 128
Gastrointestinal toxicity or irinotecan.
Hecht, J. R. (1998) · PubMed · Cited by 126
Rettie, A. E., Boberg, M., Rettenmeier, A. W., & Baillie, T. A. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68302-4 · Cited by 126
Drug Interactions with Cisapride
Michalets, E. L., & Williams, C. R. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039010-00004 · Cited by 126
Ticrynafen-Associated Hepatic Injury: Analysis of 340 Cases
Zimmerman, H. J., Lewis, J. H., Ishak, K. G., & Maddrey, W. C. (1984) · Hepatology · doi:10.1002/hep.1840040223 · Cited by 126
Lecoeur, S., Bonierbale, E., Challine, D., Gautier, J., Valadon, P., Dansette, P. M., Catinot, R., Ballet, F., Mansuy, D., & Beaune, P. H. (1994) · Chemical Research in Toxicology · doi:10.1021/tx00039a023 · Cited by 126
Non-Nucleoside HIV-1 Reverse Transcriptase (RT) Inhibitors: Past, Present, and Future Perspectives
Campiani, G., Ramunno, A., Maga, G., Nacci, V., Fattorusso, C., Catalanotti, B., Morelli, E., & Novellino, E. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612024607207 · Cited by 126
Stürmer, E., Moltke, L. L., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12045-7 · Cited by 126
Fischer, V., Vogels, B. A. P. M., Maurer, G., & Tynes, R. E. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11451-1 · Cited by 125
Thalidomide as an Anti-TNF-α Inhibitor: Implications for Clinical Use
Klausner, J. D., Freedman, V. H., & Kaplan, G. (1996) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1996.0181 · Cited by 125
Comparison of the Metabolism and Toxicity of Dapsone in Rat, Mouse and Man
Tingle, M. D., Mahmud, R., Maggs, J. L., Pirmohamed, M., & Park, B. K. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37079-x · Cited by 125
Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides.
Green, M. D., Bishop, W. P., & Tephly, T. R. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06536-5 · Cited by 124
Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism.
Smith, P. C., Benet, L. Z., & McDonagh, A. F. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08612-x · Cited by 124
Catechol-O-methyltransferase activity: A determinant of levodopa response
Reilly, D. K., Rivera‐Calimlim, L., & Dyke, D. V. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.161 · Cited by 124
Walsh, J. S. A., Reese, M. J., & Thurmond, L. M. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00059-5 · Cited by 124
Combined glutathione-S -transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity
Simon, T. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104944 · Cited by 122
Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer
Baidas, S. M., Winer, E. P., Fleming, G. F., Harris, L. N., Pluda, J. M., Crawford, J. G., Yamauchi, H., Isaacs, C. J., Hanfelt, J., Tefft, M. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2710 · Cited by 122
Cytochrome P450 2E1 is the Principal Catalyst of Human Oxidative Halothane Metabolism in Vitro
Spracklin, D. K., Hankins, D. C., Fisher, J. M., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36603-0 · Cited by 122
Gill, H., Tingle, M. D., & Park, B. K. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05797.x · Cited by 121
Haruda, F. D. (1979) · Neurology · doi:10.1212/wnl.29.11.1480 · Cited by 121
Comparative safety of the different macrolides
Rubinstein, E. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00397-1 · Cited by 121
Gardner, I. B., Leeder, J. S., Chin, T., ZAHID, N. D., & Uetrecht, J. (1998) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)13269-5 · Cited by 120
Dopamine agonist monotherapy in Parkinson's disease
Clarke, C. E., & Guttman, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11668-0 · Cited by 120
Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes
Fau, D., Lekéhal, M., Farrell, G. C., Moreau, A., Moulis, C., Feldmann, G., Haouzi, D., & Pessayre, D. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322529 · Cited by 120
Lecoeur, S., André, C., & Beaune, P. H. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09234-x · Cited by 120
Hepatotoxicity of germander in mice
Loeper, J., Descatoire, V., Lettéron, P., Moulis, C., Degott, C., Dansette, P. M., Fau, D., & Pessayre, D. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90606-8 · Cited by 119
Stiborová, M., Frei, E., Wießler, M., & Schmeiser, H. H. (2001) · Chemical Research in Toxicology · doi:10.1021/tx010059z · Cited by 119
Levy, R. H., Rettenmeier, A. W., Anderson, G. D., Wilensky, A. J., Friel, P. N., Baillie, T. A., Acheampong, A., Tor, J., Guyot, M., & Loiseau, P. (1990) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1990.144 · Cited by 119
Developmental neurotoxicity of anticonvulsants: Human and animal evidence on phenytoin
Adams, J., Vorhees, C. V., & Middaugh, L. D. (1990) · Neurotoxicology and Teratology · doi:10.1016/0892-0362(90)90092-q · Cited by 119
Interaction between phenytoin and valproic acid: Plasma protein binding and metabolic effects
Perucca, E., Hebdige, S., Frigo, G. M., et al. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.235 · Cited by 118
Hepatitis induced by traditional Chinese herbs; possible toxic components.
Kane, J., Kane, S. P., & Jain, S. (1995) · Gut · doi:10.1136/gut.36.1.146 · Cited by 118
Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues.
Schmeiser, H. H., Janssen, J. W. G., Lyons, J., Scherf, H. R., Pfau, W., Buchmann, A., Bartram, C. R., & Wießler, M. (1990) · PubMed · Cited by 117
Gardiner, C. S., Salmen, J. J., Brandt, C. J., & Stover, S. K. (1998) · Biology of Reproduction · doi:10.1095/biolreprod59.2.431 · Cited by 117
Dual effects of macrolide antibiotics on rat liver cytochrome P-450
Delaforge, M., Jaouen, M., & Mansuy, D. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90178-8 · Cited by 116
Delavirdine: A Review of its Use in HIV Infection
Scott, L. J., & Perry, C. M. (2000) · Drugs · doi:10.2165/00003495-200060060-00013 · Cited by 115
Koenigs, L. L., & Trager, W. F. (1998) · Biochemistry · doi:10.1021/bi981198r · Cited by 115
Thalidomide Inhibits Angiogenesis in Embryoid Bodies by the Generation of Hydroxyl Radicals
Sauer, H., Günther, J., Hescheler, J., & Wartenberg, M. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64714-1 · Cited by 115
Generation of free radical intermediates from foreign compounds by neutrophil-derived oxidants.
Kalyanaraman, B., & Sohnle, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111868 · Cited by 115
Njoku, D. B., Greenberg, R. S., Bourdi, M., Borkowf, C. B., Dake, E. M., Martin, J. L., & Pohl, L. R. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200202000-00003 · Cited by 114
Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug Interactions
Decker, C. J., Laitinen, L. M., Bridson, G. W., Raybuck, S. A., Tung, R. D., & Chaturvedi, P. R. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980029p · Cited by 114
Rosenblat, M., Belinky, P. A., Vaya, J., Lévy, R., Hayek, T., Coleman, R., Merchav, S., & Aviram, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13790 · Cited by 114
Brøsen, K., Zeugin, T., & Meyer, U. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.77 · Cited by 114
Arylamine N-acetyltransferases – of mice, men and microorganisms
Upton, A. M., Johnson, N., Sandy, J., & Sim, E. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01639-4 · Cited by 113
Clinical Pharmacokinetics of Imipramine and Desipramine
Sallee, F. R., & Pollock, B. G. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199018050-00002 · Cited by 113
Christ, D. D., Kenna, J. G., Hammerer, W., Satoh, H., & Pohl, L. R. (1988) · Anesthesiology · doi:10.1097/00000542-198812000-00006 · Cited by 113
Gisbert, J. P., Gomollón, F., Maté, J., & Pajares, J. M. (2002) · Digestive Diseases and Sciences · doi:10.1023/a:1017987229718 · Cited by 112
de Villiers, E. (2002) · International Journal of Cancer · doi:10.1002/ijc.10868 · Cited by 112
Psoralen Photochemotherapy of Cutaneous Disorders
Anderson, T. F., & Voorhees, J. J. (1980) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.20.040180.001315 · Cited by 112
Proposed mechanisms of action in thalidomide embryopathy
Stephens, T. D. (1988) · Teratology · doi:10.1002/tera.1420380307 · Cited by 111
Bensoussan, C., Delaforge, M., & Mansuy, D. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00477-4 · Cited by 110
Mechanism-Based Inactivation of P450 2A6 by Furanocoumarins
Koenigs, L. L., & Trager, W. F. (1998) · Biochemistry · doi:10.1021/bi980003c · Cited by 110
The metabolic fate of thalidomide
Faigle, J. W., Keberle, H., Riess, W., & Schmid, K. (1962) · Cellular and Molecular Life Sciences · doi:10.1007/bf02151479 · Cited by 110
Involvement of CYP1A2 and CYP3A4 in Lidocaine N-Deethylation and 3-Hydroxylation in Humans
Wang, J.-S., Backman, J. T., Taavitsainen, P., Neuvonen, P. J., & Kivistö, K. T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15170-7 · Cited by 110
The treatment of advanced renal cell cancer with high-dose oral thalidomide
Stebbing, J., Benson, C., Eisen, T. G., Pyle, L., Smalley, K. S. M., Bridle, H., Mak, I., Sapunar, F. J., A’Hern, R., & Gore, M. E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2025 · Cited by 109
Phase II trial of thalidomide in renal-cell carcinoma
Escudier, B. J., Lassau, N., Couanet, D., Angevin, E., Mesrati, F., Leborgne, S., Garofano, A., Leboulaire, C., Dupouy, N., & Laplanche, A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf213 · Cited by 109
Potter, D. W., & Hinson, J. A. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)75735-4 · Cited by 108
Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions.
Fabre, G., Julian, B., Saint‐Aubert, B., Joyeux, H., & Berger, Y. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08220-0 · Cited by 108
Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans
O’Reilly, R. A., Trager, W. F., Rettie, A. E., & Goulart, D. A. (1987) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1987.149 · Cited by 108
Canal, P., Gay, C., Dezeuze, A., Douillard, J., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F. M., & Mathieu-Boué, A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2688 · Cited by 108
Guillain-Barre syndrome following zimeldine treatment.
Fagius, J., OSTERMAN, P. O., Sidén, Å., & Wiholm, B. ‐. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.1.65 · Cited by 107
Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs.
Cribb, A. E., Miller, M., Tesoro, A., & Spielberg, S. P. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09508-2 · Cited by 106
Mechanisms of Acetaminophen Toxicity: Immunochemical Detection of Drug-Protein Adducts
Hinson, J., Pumford, N. R., & Roberts, D. W. (1995) · Drug Metabolism Reviews · doi:10.3109/03602539509029816 · Cited by 106
Cited by
Bruderer, R., Bernhardt, O. M., Gandhi, T., Miladinović, S. M., Cheng, L.-Y., Messner, S., Ehrenberger, T., Zanotelli, V., Butscheid, Y., Escher, C., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044305 · Cited by 1,238
Tiwari, B., Sellamuthu, B., Ouarda, Y., Drogui, P., Tyagi, R. D., & Buelna, G. (2017) · Bioresource Technology · doi:10.1016/j.biortech.2016.11.042 · Cited by 817
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Apparent activity in high-throughput screening: origins of compound-dependent assay interference
Thorne, N., Auld, D. S., & Inglese, J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.020 · Cited by 430
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Metadata
- Authors
- Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 37
- Issue
- 1
- Pages
- 41-213
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W1997486990
- Cited by
- 274
- References
- 774
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.